血管腔内髂动脉分支装置治疗髂动脉瘤:系统评价与Meta分析
该系统评价与Meta分析检索Medline、EMBASE和Cochrane数据库,纳入22项研究共1064例患者,评估血管腔内髂动脉分支装置治疗主髂动脉瘤的安全性及结局。汇总技术成功率为93%(95%CI 91-95%),30天死亡率为2%(95%CI 1-4%),随访通畅率为86%(95%CI 84-88%)。作者认为中期随访结果满意。
要点
- 纳入22项研究共1064例主髂动脉瘤患者,评估髂动脉分支装置(IBD)结局。
- 汇总技术成功率93%(95%CI 91-95%),30天死亡率2%(95%CI 1-4%)。
- 随访通畅率86%(95%CI 84-88%),内漏率12%(95%CI 8-17%)。
核心结论
- 作者认为,使用IBD治疗主髂动脉瘤在中期随访中产生满意结局。
研究设计与样本
- 系统评价与Meta分析,系统检索Medline、EMBASE和Cochrane数据库,由2名独立研究者按既定标准筛选文献并提取数据。
- 共纳入22项研究、1064例患者,评估7项结局指标。
- 采用基于卡方分布的Q检验和I²统计量评估异质性,并使用随机效应模型和固定效应模型进行Meta分析。
主要发现
- IBD汇总技术成功率为93%(95%CI 91-95%)。
- IBD治疗后30天死亡率为2%(95%CI 1-4%),30天通畅率为93%(95%CI 91-94%)。
- 随访通畅率为86%(95%CI 84-88%),内漏率为12%(95%CI 8-17%)。
- 臀部跛行率为6%(95%CI 5-8%),IBD相关再干预率为11%(95%CI 8-14%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Iliac branch devices (IBDs) have been increasingly reported for treating aortoiliac aneurysms. However, there are still concerns regarding this device. The aim of this study was to evaluate the safety and outcomes of IBDs in treating aortoiliac aneurysms by performing a systematic review and meta-analysis. METHODS: The Medline, EMBASE, and Cochrane databases were systematically searched to identify studies on the management of aortoiliac aneurysms using IBDs. Studies were reviewed and selected using defined criteria by 2 independent investigators who abstracted data on the study characteristics, study quality, and outcomes. The extracted data were presented as a rate and converted through arcsine transformations. Individual studies were evaluated and analyzed for 7 outcomes, including technical success rate, 30-day mortality, 30-day patency, follow-up patency, endoleak rate, buttock claudication, and IBD-associated reintervention. The heterogeneity of the studies was determined using the chi-squared distribution-based Q test and quantified by I2 statistics. Meta-analyses were performed using both a random effects model and fixed effects model. RESULTS: Twenty-two studies with a total of 1064 patients met the inclusion criteria and were selected for analysis. The pooled technical success rate of IBD was 93% (95% confidence interval [CI]: 91-95%). After patients were treated with the IBD, the 30-day mortality rate was 2% (95% CI, 1-4%), 30-day patency rate was 93% (95% CI, 91-94%), follow-up patency was 86% (95% CI, 84-88%), endoleak rate was 12% (95% CI, 8-17%), buttock claudication rate was 6% (95% CI, 5-8%), and IBD-associated reintervention rate was 11% (95% CI, 8-14%). CONCLUSIONS: Our study demonstrates that treating aortoiliac aneurysm with IBD produces satisfactory outcomes in midterm follow-up.
引用
- Li Y, Hu Z, Zhang J, et al. Iliac Aneurysms Treated with Endovascular Iliac Branch Device: A Systematic Review and Meta-analysis. Ann Vasc Surg. 2018. PMID: 30287293. doi:10.1016/j.avsg.2018.07.058
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。